SGLT2-话题@MedSci

#SGLT2#

82篇内容 | 3014人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1503799, encodeId=7d061503e995e, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Blood：SGLT2抑制剂依帕列净成功纠正了糖原贮积症Ib的中性粒细胞减少及其功能障碍, objectType=article, longId=192947, objectId=49b619294e48, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49b619294e48, replyNumber=0, likeNumber=57, createdTime=2020-04-26, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49b619294e48, moduleTitle=Blood：SGLT2抑制剂依帕列净成功纠正了糖原贮积症Ib的中性粒细胞减少及其功能障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49b619294e48)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503798, encodeId=c3d41503e98c1, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=“灵魂砍价”药物还能防痛风？SGLT2抑制剂成“万金油”, objectType=article, longId=186358, objectId=6e021863583f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e021863583f, replyNumber=0, likeNumber=84, createdTime=2020-01-18, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e021863583f, moduleTitle=“灵魂砍价”药物还能防痛风？SGLT2抑制剂成“万金油”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e021863583f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503797, encodeId=d59c1503e9704, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Lancet子刊：真实世界研究显示SGLT2抑制剂对糖尿病患者肾功能有获益, objectType=article, longId=186096, objectId=904518609696, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=904518609696, replyNumber=0, likeNumber=71, createdTime=2020-01-13, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=904518609696, moduleTitle=Lancet子刊：真实世界研究显示SGLT2抑制剂对糖尿病患者肾功能有获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=904518609696)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503796, encodeId=cd351503e96d6, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, objectType=article, longId=185842, objectId=eae01858423e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eae01858423e, replyNumber=0, likeNumber=80, createdTime=2020-01-08, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eae01858423e, moduleTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eae01858423e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503795, encodeId=1e031503e958c, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=降糖药钠- 葡萄糖共转运蛋白2SGLT2 抑制剂成心衰治疗基石之一, objectType=article, longId=184434, objectId=14d118443425, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14d118443425, replyNumber=0, likeNumber=70, createdTime=2019-12-09, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14d118443425, moduleTitle=降糖药钠- 葡萄糖共转运蛋白2SGLT2 抑制剂成心衰治疗基石之一, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14d118443425)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503794, encodeId=4bbe1503e9457, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=SGLT2抑制剂临床应用专家指导建议解读 | CDS2019, objectType=article, longId=183456, objectId=a0c5183456e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0c5183456e9, replyNumber=0, likeNumber=69, createdTime=2019-11-24, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0c5183456e9, moduleTitle=SGLT2抑制剂临床应用专家指导建议解读 | CDS2019, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0c5183456e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503793, encodeId=ed951503e9388, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=全球SGLT2i非糖尿病人群数据震撼发布丨葛均波院士、江晨恩教授两大牵头研究者解读DAPA-HF新证据, objectType=article, longId=183273, objectId=f3641832e38a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3641832e38a, replyNumber=0, likeNumber=79, createdTime=2019-11-21, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3641832e38a, moduleTitle=全球SGLT2i非糖尿病人群数据震撼发布丨葛均波院士、江晨恩教授两大牵头研究者解读DAPA-HF新证据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3641832e38a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503792, encodeId=c1b41503e92a2, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, objectType=article, longId=183195, objectId=6133183195fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6133183195fa, replyNumber=0, likeNumber=58, createdTime=2019-11-20, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6133183195fa, moduleTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6133183195fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503791, encodeId=6ec21503e91e9, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, objectType=article, longId=181704, objectId=6557181e048a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6557181e048a, replyNumber=0, likeNumber=54, createdTime=2019-10-23, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6557181e048a, moduleTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6557181e048a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503790, encodeId=c2091503e90b5, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=阿斯利康的SGLT2抑制剂达格列嗪治疗心力衰竭获得FDA的快速通道认证, objectType=article, longId=179624, objectId=489d1e96248e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=489d1e96248e, replyNumber=0, likeNumber=64, createdTime=2019-09-19, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=489d1e96248e, moduleTitle=阿斯利康的SGLT2抑制剂达格列嗪治疗心力衰竭获得FDA的快速通道认证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=489d1e96248e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503789, encodeId=46161503e892a, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Lancet Diabetes Endo：SGLT2抑制剂的肾脏保护作用, objectType=article, longId=179046, objectId=34e61e9046bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34e61e9046bc, replyNumber=0, likeNumber=81, createdTime=2019-09-08, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34e61e9046bc, moduleTitle=Lancet Diabetes Endo：SGLT2抑制剂的肾脏保护作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34e61e9046bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503788, encodeId=7dd31503e8860, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=BMJ：SGLT2抑制剂可降低糖尿病患者心力衰竭风险, objectType=article, longId=178463, objectId=a7aa1e846397, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7aa1e846397, replyNumber=0, likeNumber=107, createdTime=2019-09-01, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7aa1e846397, moduleTitle=BMJ：SGLT2抑制剂可降低糖尿病患者心力衰竭风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7aa1e846397)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503787, encodeId=dbd71503e8726, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=SGLT2抑制剂达格列净在心衰研究中显示出益处, objectType=article, longId=178048, objectId=18661e804804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18661e804804, replyNumber=0, likeNumber=85, createdTime=2019-08-22, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18661e804804, moduleTitle=SGLT2抑制剂达格列净在心衰研究中显示出益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18661e804804)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503786, encodeId=dca61503e8638, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=AZ的SGLT2抑制剂Forxiga在欧盟扩展用于II型糖尿病, objectType=article, longId=177009, objectId=bd4e1e700904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd4e1e700904, replyNumber=0, likeNumber=156, createdTime=2019-08-08, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd4e1e700904, moduleTitle=AZ的SGLT2抑制剂Forxiga在欧盟扩展用于II型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd4e1e700904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503785, encodeId=86c81503e8584, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂与生殖器真菌感染和尿路感染的风险, objectType=article, longId=174707, objectId=386c1e470775, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=386c1e470775, replyNumber=0, likeNumber=29, createdTime=2019-07-04, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=386c1e470775, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂与生殖器真菌感染和尿路感染的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=386c1e470775)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503784, encodeId=30c51503e8423, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=慢性心力衰竭：FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格, objectType=article, longId=174322, objectId=0d4b1e4322ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d4b1e4322ee, replyNumber=0, likeNumber=82, createdTime=2019-06-29, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d4b1e4322ee, moduleTitle=慢性心力衰竭：FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d4b1e4322ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503783, encodeId=96e81503e8328, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=2019 ADA：阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病, objectType=article, longId=168050, objectId=2d6716805018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6716805018, replyNumber=0, likeNumber=134, createdTime=2019-06-12, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6716805018, moduleTitle=2019 ADA：阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d6716805018)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503782, encodeId=b8551503e8263, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=SGLT2降糖药致生殖器感染"发酵" 已上市药物几乎都中枪, objectType=article, longId=165872, objectId=18411658e2e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18411658e2e0, replyNumber=0, likeNumber=66, createdTime=2019-05-13, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18411658e2e0, moduleTitle=SGLT2降糖药致生殖器感染"发酵" 已上市药物几乎都中枪, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18411658e2e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503781, encodeId=938c1503e8117, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, objectType=article, longId=164340, objectId=bc7c1643405d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7c1643405d, replyNumber=0, likeNumber=31, createdTime=2019-04-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7c1643405d, moduleTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7c1643405d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503780, encodeId=9b6b1503e804f, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, objectTitle=美国FDA拒绝了双重SGLT1和SGLT2抑制剂Zynquista治疗1型糖尿病的申请, objectType=article, longId=162858, objectId=f5fa1628585f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5fa1628585f, replyNumber=0, likeNumber=75, createdTime=2019-03-26, rootId=0, userName=jiekemin, userId=3afa9693555, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5fa1628585f, moduleTitle=美国FDA拒绝了双重SGLT1和SGLT2抑制剂Zynquista治疗1型糖尿病的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5fa1628585f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SGLT2

2020-05-29

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Blood：SGLT2抑制剂依帕列净成功纠正了糖原贮积症Ib的中性粒细胞减少及其功能障碍

2020-04-26

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

“灵魂砍价”药物还能防痛风？SGLT2抑制剂成“万金油”

2020-01-18

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Lancet子刊：真实世界研究显示SGLT2抑制剂对糖尿病患者肾功能有获益

2020-01-13

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查

2020-01-08

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

降糖药钠- 葡萄糖共转运蛋白2SGLT2 抑制剂成心衰治疗基石之一

2019-12-09

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

SGLT2抑制剂临床应用专家指导建议解读 | CDS2019

2019-11-24

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

全球SGLT2i非糖尿病人群数据震撼发布丨葛均波院士、江晨恩教授两大牵头研究者解读DAPA-HF新证据

2019-11-21

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善

2019-11-20

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险

2019-10-23

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

阿斯利康的SGLT2抑制剂达格列嗪治疗心力衰竭获得FDA的快速通道认证

2019-09-19

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Lancet Diabetes Endo：SGLT2抑制剂的肾脏保护作用

2019-09-08

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

BMJ：SGLT2抑制剂可降低糖尿病患者心力衰竭风险

2019-09-01

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

SGLT2抑制剂达格列净在心衰研究中显示出益处

2019-08-22

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

AZ的SGLT2抑制剂Forxiga在欧盟扩展用于II型糖尿病

2019-08-08

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

Diabetes Obes Metab：SGLT2抑制剂与生殖器真菌感染和尿路感染的风险

2019-07-04

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

慢性心力衰竭：FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格

2019-06-29

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

2019 ADA：阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病

2019-06-12

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

SGLT2降糖药致生殖器感染"发酵" 已上市药物几乎都中枪

2019-05-13

仁者大医 (审核中...)

前往app查看评论内容

#SGLT2#

III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险

2019-04-17

jiekemin (审核中...)

前往app查看评论内容

#SGLT2#

美国FDA拒绝了双重SGLT1和SGLT2抑制剂Zynquista治疗1型糖尿病的申请

2019-03-26

科室
- - 订阅+
  - 更多科室
工具
服务